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Purpose: Activity behaviors of breast cancer survivors (BCS) during treatment are unlikely to be 
at levels sufficient enough to gain health benefits. Previous activity research among BCS have 
been mainly post treatment and generally cross-sectional. This study aimed to determine the 
prevalence and changes in objectively measured moderate-to-vigorous physical activity 
(MVPA), light (LPA) and sedentary behavior (SED) among BCS undergoing adjuvant/palliative 
therapy. 
Methods: Participants completed baseline surveys and wore accelerometers to measure activity 
during waking hours during treatment and again 6 months later. Hierarchal Linear Modelling 
(HLM) was used to determine changes.  
Results: 77 BCS participated. 91% provided PA data for ≥3 valid days at baseline (T1) and 72% 
at 6 months (T2); 29% met PA guidelines at T1 and 41% at T2. Daily LPA and SED did not 
change from T1 to T2 (133 vs. 138 minutes; 595 vs 597 minutes). Controlling for BMI at the 
intercept, HLM revealed MVPA significantly increased from T1 to T2 (+5.62, p=.015).  
Conclusion: An increase in objectively measured total daily MVPA over six months was found; 
at which time, fewer BCS were currently receiving chemo- or radiotherapy and may theoretically 
be feeling better. However, fewer T2 measures may bias and artificially inflate the results. 
Though total MVPA minutes increased at T2, less than half were meeting guidelines and had 
high amounts of LPA/SED during treatment with insignificant change over time (71% at T1; 
59% at T2). Practitioner intervention may help reduce SED while increasing LPA and MVPA 
behavior among those currently on treatment.  
Manuscript word count: 3612 
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 Recent research shows that engaging in physical activity (PA) after a cancer diagnosis 
can help lower the risk of breast cancer-specific and all-cause mortality.1, 2 PA interventions 
during and after adjuvant/palliative therapy have been shown to be safe and feasible1, 3-6 and can 
result in improvements in body composition, cardiovascular fitness, and chemotherapy 
completion rates in breast cancer survivors (BCS).1, 7 Despite the numerous benefits associated 
with PA, research suggests that as many as 85% of BCS are not active enough to meet the 
recommended activity.8, 9 Accelerometer studies show that the proportion of waking hours spent 
in moderate-to-vigorous PA (MVPA) is quite small, with only about 3% of waking hours being 
allocated to MVPA and spend an average 8 hours per day sedentary.8-11  
The majority of prior research focuses on those who have completed treatments and those 
without advanced disease. While there may be more barriers to activity during treatment, much 
less is known about levels of free-living activity among BCS currently on treatment, particularly 
MVPA.1, 12 Studies have shown that engaging in activity while on treatment can help mitigate 
side-effects and therefore, is recommended by the American Cancer Society.13 This study 
addresses this important research gap with an aim to investigate free-living activity levels in BCS 
while on treatment. 
In addition to a significant proportion of BCS being inactive, recent research in non-
diseased populations has directed its attention to sedentary behavior (SED).14 Studies show that 
high levels of SED is negatively associated with health-related QoL (HRQoL) outcomes like 
increased fatigue and lower physical well-being,10 and clinical risk factors linked to longevity in 
BCS independent of MVPA levels such as increased waist circumference and BMI.11 Cross-
sectional studies suggest that BCS spend approximately 55% to 66% of their day engaging in 
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sedentary activities,8, 10 which suggests that upwards of 600 minutes (i.e., 10 hours) per day is 
spent engaged in SED. This is comparable to older adult women in the general population 
assessed by the Canadian Health Measures Survey who also accumulated 600 minutes of SED 
during their waking hours.15 
Recent research among the general population16-19 and some chronic disease 
populations19-22 have also demonstrated the potential of using standing and light intensity PA 
(LPA) to break up sitting time, rather than structured MVPA, to improve health outcomes.23 
Research also suggests that MVPA and SED should not be examined in isolation, but rather their 
interplay should be examined. The literature has identified four mutually exclusive categories24-27 
based on these behaviors (Figure 3) and found that up to 47% were classified as Inactive; a group 
that has been shown to have the poorest health and QoL measures compared to any other 
category.24-27 We sought to measure LPA and categorize the activity behavior into one of four 
groups in a group of breast cancer survivors to make an important addition to the literature.   
--Figure 1 near here-- 
To address these gaps in the literature, the current study’s first objective was to assess the 
potential changes over six months in MVPA, LPA, and SED of BCS during adjuvant or 
palliative therapy. As with previous accelerometer studies, we hypothesized that sedentary time 
would make up the largest proportion of waking hours with little MVPA or LPA8-11 performed 
and that these results would remain stable from baseline to follow-up. The second exploratory 
objective of this study was to determine the behavioral categories of BCS at baseline and follow-
up. We also hypothesized that the majority of BCS would be classified as ‘Inactive’ at both time-
points.24-27 
Materials and Methods 
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Study design and participants 
A longitudinal study of free-living activity among BCS undergoing adjuvant or palliative 
treatment was employed. Participants were eligible if they were female patients with breast 
cancer who met the following criteria: 1) ≥ 18 years of age; 2) able to read and write English; 3) 
were currently receiving adjuvant or palliative therapy (i.e., chemotherapy, trastuzumab, 
radiation therapy, or hormone therapy). Exclusion criteria included those with carcinoma in-situ 
or those who are unable to participate due to significant medical or physical limitations.  
Participants did not have to be on treatment at the follow up measure after 6 months.  
Recruitment 
Participants were recruited from the Nova Scotia Cancer Clinic at the Queen Elizabeth II 
Health Science Centre – Victoria General Site one of two ways. The first way, potentially 
eligible patients were screened by a member of the oncology care team, and those that indicated 
an interested in participating were given study information and consented by a RA. Next, the 
participant was fitted with an accelerometer and GPS unit that was worn for all waking hours of 
the day for 9 consecutive days. She was asked to record the time she put the devices on and took 
them off each day (i.e., via a wear time log) and the types of activities she engaged in (i.e., via a 
physical activity log). Finally, the participant was asked to ensure she completed the PA behavior 
questionnaire at the beginning of the measurement period (day 1), then the SED questionnaire at 
the end of the measurement period (day 9). Once completed, an appointment was made to collect 
the materials either in the clinic or the RA would meet the participant at her home. The second 
method of recruitment was via posters in the clinic. Here, a potential participant would contact 
the RA directly and if she was interested, she was asked for permission to contact her oncology 
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health care team to confirm eligibility. If she remained eligible, she was contacted to obtain 
consent and provide study package materials.  
Approximately 5½ months later, the participant was contacted by phone to collect the 6-
month assessment.  If she was no longer interested in participating, she was thanked for her time. 
If she agreed to do the assessment, an appointment was made for the RA to go to her home and 
fit her with the accelerometer and GPS unit and provide the same logs and questionnaire.  An 
appointment was then made to pick up the devices after the 9-day wear time period. For both 
assessments, if a device malfunctioned or had inadequate data, the participant was asked to wear 
the devices for another 9 consecutive days. Finally, for purposes of the current paper, only the 
accelerometer data was analyzed as the wear-time logs were not consistently completed. This 
study was approved by the (then) Capital District Health Authority Research Ethics Board.  
Measures 
Demographic, medical, and behavioral information 
Demographic and medical variables were self-report and chart review. Demographic 
variables included age, marital status, ethnicity, years of education, employment status, income 
level, and height and weight to calculate body mass index (BMI). Medical variables collected 
were disease stage, month and year of diagnosis, treatment type, length of treatment, 
comorbidities, and perceived general health. Health behaviors measured were smoking status, 
alcohol consumption, and sleep habits.  
Physical activity and sedentary behavior 
MVPA was measured via the Actigraph GT3X accelerometer which has been shown to 
be a valid and reliable tool for personal activity measurement.28, 29 In brief, the accelerometer is 
designed to detect vertical accelerations ranging in magnitude from 0.05 to 2.00 g with a 
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frequency response of 0.25 to 2.50 hertz. These parameters allow for the measurement of normal 
human motion while rejecting high frequency vibrations from other sources. The accelerometer 
was placed on the right hip of each patient and held firmly in place via a belt clip to ensure 
consistent positioning. The accelerometer data was reduced to five-second counts (or epochs) 
and categorized according to physical activity intensity. Participants were asked to wear the 
accelerometer for nine consecutive days. If data were present for all nine days, the first and last 
day were removed. However, if the participant didn’t have seven valid days between days two 
and eight, days one and/or nine were included to obtain as many valid days as possible up to 
seven.  A day was considered valid if wear time was at least 600 minutes.10, 26 Using Actilife v6 
software, for each valid day, time spent in sedentary, light, moderate and vigorous activity was 
calculated using the following accepted cut-points30: <100 counts per minute (cpm) for 
sedentary, 100 - < 2020cpm for light, 2020 - <5999 for MVPA. Time spent in bouts of MVPA 
lasting 10 minutes or more were also calculated; this measure was used to determine those 
meeting PA guidelines (i.e., 0 if ≤ 150 minutes per week of MVPA; 1 if ≥ 150 minutes per week 
of MVPA). Finally, the daily time spent in each intensity of activity (i.e., MVPA, LPA, and 
SED) was calculated as a percentage. As with previous studies objectively measuring activity in 
BCS, participants were included in this analyses if they provided at least three valid days of 
accelerometer data.10 All measures were divided by the number of valid days to provide a ‘per 
day” outcome.  
Statistical Analyses 
Analyses were completed using ISM SPSS Statistics 22 (IBM Analytics, Armonk, NY) 
and HLM7 Student Version (SSI, Inc. Skokie, IL). Descriptive statistics were used to describe 
the sample and the activity behavior at baseline and 6 months. Skewness was determined and 
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data were normalized where applicable. To address objective 1 (i.e., to determine potential 
changes in activity variables), HLM was used. Prior to conducting the main analyses, however, 
preliminary models were run with each medical and demographic variable to determine its 
potential relationship with a given activity outcome variable (i.e., to identify potential covariates 
for the main HLM models). Specifically, a Level-1 model was specified wherein the intercept 
(e.g., MVPA at baseline) was allowed to vary randomly (i.e., vary across BCS) and the slope for 
the linear trend was constrained to be fixed (i.e., the same across BCS). At Level-2, each medical 
and demographic variable was entered separately to predict the intercept and slope.  Variables 
that were significant (p≤0.05) were then retained as covariates for the main HLM analyses. Once 
the covariates were identified, the next series of analyses examined the potential changes in each 
activity variable controlling for the covariates. To address objective 2 (i.e., to determine the 
proportion of BCS that are in each behavioral category), quartiles were created for the minutes 
per day of SED. As there are no defined criteria for being low vs. highly sedentary in BCS, we 
assigned the bottom quartile to be ‘low sedentary behavior’.24 Next, using the baseline data, four 
mutually exclusive groups were determined based on whether participants met MVPA guidelines 
or not, and whether they had high or low levels of SED.24, 26 Finally, we examined the number of 
BCS who remained in the same category or changed categories at 6 months.  
Results 
Participants 
 The detailed flow of participants can be found in Figure 1. There were 114 BCS that 
either were identified as eligible by the oncology care team (n=102) or directly contacted the RA 
after seeing a recruitment poster in the cancer clinic (n=12). Of those deemed eligible and 
potentially interested in the study (n=98), 77 provided informed consent and completed baseline 
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measures (Table 1). The majority of participants were Caucasian (97%), married (67%), 
employed full- or part-time (51%), non-smokers (87%), social drinkers (64%), had 
postsecondary education (51%), and a household income of ≥$75,000 (51%). Average age and 
BMI were 57 (±9.4) years and 27.9 (±6.9) kg/m2 respectively. Most participants reported stage II 
disease (44%), currently receiving one or more type of therapy (95%), reported fewer than 2 
comorbidities (75%), and a perceived general health of very good or excellent (56%). A small 
proportion of participants (4%) were receiving palliative treatment at baseline. At the 6-month 
follow-up, 57 provided completed measures for a 74% retention rate. At T2, 20% of participants 
were not currently receiving treatment. The reasons given for not completing follow-up measures 
were ‘no longer interested’ (n=6), ‘health issues’ (n=5), ‘too busy’ (n=2), ‘work conflict’ (n=1), 
and ‘felt demotivating’ (n=1). We were unable to contact four participants for follow-up and 
only collected survey data for one participant.  
--Figure 2 near here-- 
--Table 1 near here-- 
Physical activity and sedentary behavior 
 Detailed MVPA, LPA, and SED results can be found in Table 2. At baseline, participants 
were accumulating a daily average of 40.0, 132.9, and 594.7 minutes per day of MVPA, light, 
and SED. Total MVPA in bouts was an average 15.5 minutes per day; 29% of the sample were 
meeting the PA guidelines; approximately 77% of the BCS’ day was spent sedentary.   
--Table 2 near here-- 
Changes in physical activity and sedentary behavior 
Unadjusted models showed significant changes in total MVPA minutes (+5.87; p=.012) 
and MVPA in bouts (+4.87; p=.016). No significant change was found for either light (+4.23; 
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p=.241) or sedentary minutes (-2.82; p=.701). We found that BMI had a significant influence on 
the intercept for MVPA with higher BMIs associated with fewer MVPA minutes. No other 
characteristics were found to be significant; however, BMI was kept in the final models for each 
activity variable to keep the covariates consistent across models. Final adjusted models found the 
changes in total MVPA minutes (+5.62; p=.015) and MVPA in bouts (+4.72; p=.020) remained 
significant. The non-significant changes in LPA (+4.12; p=.257) SED minutes (-2.92; p=.693) 
also remained (see Table 3).  
--Table 3 near here— 
--Figure 3 near here-- 
Behavioral categories  
To address objective 2, participants were classified into behavioral categories in the 
following proportions at baseline: 9% Busy Bees; 20% Sedentary Exercisers; 16% Light Movers; 
and 56% Inactive. At 6-month follow-up, classifications were as follows: 13% Busy Bees; 29% 
Sedentary Exercisers; 13% Light Movers; and 46% Inactive. Figure 2 shows the change in 
behavioral categories from baseline to follow-up. 
--Figure 4 near here-- 
Discussion  
 This study was among the first to examine changes in objectively measured SED, LPA, 
and MVPA in a sample of BCS undergoing active treatment. We found that BCS are spending 
most of their day (i.e., 77% of their waking time) engaged in sedentary activities with little time 
spent in LPA (17%) or MVPA (5%). Further, results showed that SED and LPA remained stable 
over the 6-month period. These findings are consistent with research among BCS post-treatment 
and studies with other cancer types8-10, 31 and the general population.25, 26 Given the emerging 
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evidence of the health risks associated with high amounts of SED and low levels of LPA,8, 19, 23, 
24 future research needs to focus on strategies for reducing the time spent in SED and increasing 
the time spent in LPA throughout the breast cancer journey. For example, recent studies have 
highlighted displacing sedentary time with LPA as a way of reducing the risks of SED among 
other populations such as people with diabetes.16-19, 22, 23  
Reducing the amount of time sitting by incorporating more time in LPA was found to be 
an effective method of managing symptoms in people with type 2 diabetes, as was reported in a 
recent proof-of-concept study.22 This study compared three activity regimens over three weeks. 
Results showed similar beneficial effects in both the “Sit Less” and “Exercise” activity regimens 
compared to the “Sitting”’ regimen indicating that breaking up sitting time with standing or 
LPA, such as walking, may be a more appropriate intervention for populations unable to perform 
activities at a higher intensity.19-23 It is often easier for chronic disease populations to focus 
simply on moving more whenever possible rather than trying to get enough MVPA minutes to 
meet PA guidelines.19-23 Therefore, this strategy may be applicable to BCS and should be a focus 
of future research.   
In contrast to the results published by Sabiston and colleagues, we found a significant 
increase in MVPA from baseline to 6 months. They assessed BCS’ post-treatment activity levels 
every three months for twelve months and found that sedentary activity was high and remained 
stable over time (ranging from 77.6 to 78.6% over the year).9 They also showed MVPA levels 
significantly decreased over time. The current study contributes additional knowledge about PA 
among BCS patients by measuring MPVA and SED during treatment. While our average 
accelerometer wear-time was slightly lower than previous studies,8-11, 32 it is unclear whether this 
difference is significant enough to account for the more active sample. One explanation may be 
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that Sabiston’s sample was post-treatment, whereas ours was during treatment. Near the end of 
curative intent treatment tends to be when women are starting to feel better and may be moving 
around more than they were in the previous months while on adjuvant therapy. Further potential 
explanations are discussed in the limitations section.  
 When classified into behavioral categories, our results showed most participants were 
identified as “Inactive” at both time-points. These results supported our hypothesis and are 
similar to previous studies in non-diseased populations.24-27 Research shows an association 
between those who are more active having a reduced risk of adverse breast cancer outcomes (e.g. 
recurrence and death);33 however, there is little research examining the combination of sedentary 
behavior and MVPA. A recent study by Maddison and colleagues (2016) analyzed data from the 
National Health and Nutritional Examination Survey (NHANES) in the United States to 
characterize activity profiles and determine any associated cardiovascular disease (CVD) risk 
based on similar behavioral categories as we reported.26 They found that when compared to the 
Busy Bee group, the Inactive group had the highest CVD risk followed by the Light Movers, 
with no difference between the Sedentary Exercisers. Due to our small sample size, we were 
under powered to perform association analyses across the four groups. A recent cohort study 
among breast cancer survivors examined risk of cardiovascular events and also reported that 
incidence had a graded reduction as exercise levels increased.34 As BCS have a higher risk of 
subsequent comorbidities, like heart disease,35, 36 it is important that future research assess health 
outcomes related to these behavioral categories and the interplay of MVPA and SED.  
 Despite the novel findings of the study, there are limitations that need to be considered. 
First, the transparency of the type of study being performed may have resulted in biased sample 
of more active women. It is a common limitation in behavior change research to have selection 
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bias with those recruited being more likely to be more active than those that declined 
participation. Future studies should attempt to recruit the less motivated population. Second, the 
majority of the sample was white, well-educated, and wealthier. Future research, particularly 
regarding SED, should aim to recruit a more representative sample. Third, the smaller sample 
size meant we were underpowered to ascertain which demographic and/or clinical variables were 
more likely to belong to a particular behavioral grouping and future research needs to address 
this issue, especially for the various treatment types that may impact activity levels differently. In 
addition, there may be other unknown comorbidities or occult disease (e.g. recurrence or 
treatment effects) that may impact activity levels that we are unable to determine. Finally, most 
participants that dropped out indicated either lack of interest or health concerns as their reasons 
for doing so. These participants may have been less likely to have improvements in their activity 
levels leaving us with a more active sample for the follow-up. Future studies should attempt to 
recruit a larger sample to ensure measures are robust enough to determine meaningful changes. 
Additionally, efforts to retain participants for follow-up measures are necessary to ensure results 
are representative.  
 This is the first longitudinal study to examine objective measures of activity among a 
sample of BCS undergoing adjuvant or palliative therapy. It adds to the literature of 
accelerometer studies among cancer survivors that shows high levels of sedentary activity with 
comparatively low LPA and MVPA. Additionally, this is the first study to classify BCS into 
behavioral categories, which highlighted the importance of examining both physical activity and 
sedentary behavior concurrently rather than separately, which is the current norm. Though 
research has shown behavioral interventions targeting MVPA to be modestly successful,1, 12 they 
do little to address LPA or sedentary behavior. Future research among cancer survivors should 
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build on results from non-diseased populations that shows interventions that target MVPA, LPA 
and sedentary behavior are more effective at changing sedentary behavior than MVPA 
interventions alone.20-22, 24-27 
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Table 1. Baseline demographic, medical, and behavioral characteristics of breast cancer 
survivors (n=77) in Nova Scotia, Canada. 
Table 2. Average activity measures at baseline and 6 month follow up for breast cancer survivors 
with ≥3 valid days of accelerometer data. 
Table 3. Results from the hierarchical linear modeling analyses examining change over the 6-
month period for the activity variables 
Figure legends 
Figure 1. Behavioral categories based on whether they are meeting the PA guidelines of 150 
minutes per week (High MVPA vs. Low MVPA) and whether they are accumulating high 
amounts of sedentary minutes (High SED vs. Low SED). aCategories are derived from data 
driven quartiles. Following a conservative approach, Q1 was determined to be the “low amount 
of sedentary time” group. 
Figure 2. Detailed flow of participants through the study.  
Figure 3. Average minutes of activity at T1 and T2. 3a indicates the average daily minutes in 
bouts of MVPA; 3b indicates the average daily total minutes in MVPA; 3c indicates the average 
daily minutes in SED; 3d indicates the average daily minutes in LPA.  
Figure 4. Number of participants in four mutually exclusive categories at baseline and the change 
at 6 months. 2a indicates the distribution of baseline Busy Bees at follow-up; 2b indicates the 
distribution of baseline Sedentary Exercisers at follow-up; 2c indicates the distribution of 
baseline Light Movers at follow-up; 2d indicates the distribution of baseline Inactives at follow-
up. 
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Table 1. Baseline demographic, medical, and behavioural characteristics of breast cancer survivors (n=77) 
in Nova Scotia, Canada.a 
 
Demographic/ Behaviour Variables N (%) 
  
Age [Mean (SD)] 56.8 (9.4) 
≤ 59 24 (25%) 
60-69 41 (43%) 
≥ 70 30 (32%) 
  
Ethnic origin  
White 76 (99%) 
Other 1 (1%) 
  
Marital status  
Married/Partner 52 (68%) 
Not married 25 (32%) 
  
Education  
Total years of formal schooling 14.9 (2.7) 
  
Family Income   
< 60,000 23 (32%) 
≥ 60,000-99,999 25 (36%) 
≥ 100,000 23 (32%) 
  
Employment   
Employed 38 (51%) 
Not employed 37 (49%) 
  
Smoking status  
Not at all 67 (87%) 
Occasionally 2 (3%) 
Daily 8 (10%) 
  
Alcohol consumption per week   
None 38 (50%) 
1-2 days 23 (30%) 
3-4 days 9 (12%) 
5 or more days 6 (8%) 
  
Disease Stage   
Stage I 18 (27%) 
Stage II 30 (44%) 
Stage III 16 (23%) 
Stage IV 4 (6%) 
  
Current Treatmentb,c  
Chemotherapy 31 (40%) 
Radiation therapy 30 (39%) 
Hormone therapy 50 (65%) 
  
Number of current treatments at baselinec  
1 47 (61%) 
2 14 (18%) 
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3 12 (16%) 
  
Time since diagnosis in Months [Mean (SD)]c 22.5 (36.6) 
< 5 years 70 (91%) 
≥ 5 years 7 (9%) 
  
Co-morbidity status  
Less than 2 co-morbidities 58 (75%) 
2-3 co-morbidities 12 (16%) 
≥ 4 co-morbidities 7 (9%) 
  
Body mass index [Mean (SD)]  27.9 (6.9) 
Healthy weight  28 (39%) 
Overweight  23 (32%) 
Obese  21 (29%) 
 
a Values given are N(%) unless otherwise specified. 
b May have been on more than one treatment, percentages do not add up to 100% 
c Data from chart review 
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Table 2. Average activity measures at baseline and 6 month follow up for breast cancer survivors with ≥3 









Average daily wear time 767.7 (80.55) 780.1 (78.77) 
 
Average daily MVPA minutes 40.0 (21.86) 45.9 (23.63) 
 
Average daily LPA minutes 132.9 (37.59) 138.1 (37.09) 
 
Average daily Sedentary minutes 594.7 (74.01) 597.3 (65.27) 
 
Percent of day MVPA 5.3% 5.9% 
 
Percent of day LPA 17.2% 17.6% 
 
Percent of day Sedentary 77.3% 76.5% 
 
Average daily MVPA Bout Duration 15.5 (15.45) 20.4 (18.32) 
 
Meeting PA guidelines 29% 41% 
 
Abbreviations: MVPA, moderate-to-vigorous physical activity; LPA, light physical activity; PA, physical activity 
a Values given are mean (standard deviation). 
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Table 3. Results from the hierarchical linear modeling analyses examining change over the 6-month 
period for the activity variables.a 
 
Outcome Intercept Slope p-value 
Daily MVPA minutes 39.99 5.62 .015 
Daily MVPA in Bouts 15.49 4.72 .020 
Daily LPA minutes 132.90 4.12 .257 
Daily SED minutes 594.72 -2.92 .693 
 
Abbreviations: MVPA, moderate-to-vigorous physical activity; LPA, light physical activity; SED, sedentary 
behaviour.  
 
aAll analyses controlled the intercept for BMI at level-2 based on preliminary covariate analyses 
 
  










Busy Bee Sedentary Exerciser 
Low MVPA 
(<150 minutes) 


































Lost to follow-up (n=20) 
     No response (n=7) 
     Lost interest (n=8) 
     Other reason (n=5) 
Non-participants (n=37) 
     Ineligible (n=16) 
     Declined (n=21) 
57 participants completed both T1 
and T2 measures 
77 breast cancer survivors provided 
informed consent and completed 
baseline measures 
114 breast cancer patients agreed to 
talk to (n=102) or directly contacted 
the RA (n=12) about the study 
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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) If applicable, explain how loss to follow-up was addressed 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analyzed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
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Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 
and information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of 
interest 
(c) Summarize follow-up time (eg, average and total amount) 
Outcome data 15* Report numbers of outcome events or summary measures over time 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear which 
confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk 
for a meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
Discussion 
Key results 18 summaries key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Generalizability 21 Discuss the generalizability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background 
and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article 
(freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine 
at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
 
